Carfilzomib
Carfilzomib, Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target proteasome subunit beta type-5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Carfilzomib (discontinued: Carfilzomib)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kyprolis | New Drug Application | 2024-09-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CARFILZOMIB, KYPROLIS, ONYX PHARMS AMGEN | |||
| 2023-08-20 | I-842 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Carfilzomib, Kyprolis, Onyx Pharms Amgen | |||
| 9493582 | 2033-02-27 | DP | |
| RE47954 | 2029-10-21 | U-3449 | |
| 7737112 | 2027-12-07 | DP | |
| 7417042 | 2026-07-20 | DS, DP | |
| 7232818 | 2025-04-14 | DS, DP | |
| 7491704 | 2025-04-14 | U-1260, U-2319, U-2320, U-2947 | |
| 8129346 | 2025-04-14 | U-1260, U-2319, U-2320, U-2947 | |
| 8207125 | 2025-04-14 | DS, DP | |
| 8207126 | 2025-04-14 | DP | |
| 8207127 | 2025-04-14 | U-1260, U-2319, U-2320, U-2947 | |
| 8207297 | 2025-04-14 | DS, DP | |
HCPCS
Code | Description |
|---|---|
| J9047 | Injection, carfilzomib, 1 mg |
Clinical
Clinical Trials
254 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 73 | 119 | 31 | 2 | 21 | 207 |
| Plasma cell neoplasms | D054219 | — | — | 71 | 117 | 28 | 2 | 16 | 196 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | 3 | 1 | — | 1 | 7 |
| Residual neoplasm | D018365 | — | — | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 18 | 8 | — | — | — | 21 |
| Neoplasms | D009369 | — | C80 | 7 | 4 | — | — | — | 8 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 8 | 2 | — | — | — | 8 |
| Smoldering multiple myeloma | D000075122 | — | — | — | 6 | — | — | — | 6 |
| Carcinoma | D002277 | — | C80.0 | 3 | 3 | — | — | — | 5 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | 4 | — | — | — | 5 |
| T-cell lymphoma | D016399 | — | — | 5 | 2 | — | — | — | 5 |
| Hematologic neoplasms | D019337 | — | — | 5 | 1 | — | — | — | 5 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 1 | — | — | — | 4 |
| Mantle-cell lymphoma | D020522 | — | — | 2 | 2 | — | — | — | 4 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 7 | — | — | — | 1 | 8 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | — | — | — | 1 | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 3 | — | — | — | 1 | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | 1 | 2 |
| B-cell lymphoma | D016393 | — | — | 2 | — | — | — | — | 2 |
| Mycoses | D009181 | — | B35-B49 | 2 | — | — | — | — | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | 2 | — | — | — | — | 2 |
| T-cell lymphoma cutaneous | D016410 | — | — | 2 | — | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 2 | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carfilzomib |
| INN | carfilzomib |
| Description | Carfilzomib is a synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma It has a role as an antineoplastic agent and a proteasome inhibitor. It is a tetrapeptide, a member of morpholines and an epoxide. |
| Classification | Small molecule |
| Drug class | proteozome inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 |
Identifiers
| PDB | — |
| CAS-ID | 868540-17-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL451887 |
| ChEBI ID | 65347 |
| PubChem CID | 11556711 |
| DrugBank | DB08889 |
| UNII ID | 72X6E3J5AR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kyprolis – Ligand Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Kyprolis – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Kyprolis – Onyx Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,914 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,546 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use